First-in-class antiviral compound against HSV-1 and HSV-2 acyclovir-resistant strains

Patent number:

EP25382332

No items found.

LN-7 is a new endonuclease Inhibitor that prevents Herpes Simplex Virus 1 and 2 (HSV-1 and 2) replication in preclinical in vitro and in vivo studies, postulating as novel antiviral candidate for prevention, conventional antiviral resistant HSV and combination therapy against herpesvirus.

Countries:

Spain

Regions:

Community of Madrid

Centers:

CSIC, UNIVERSIDAD AUTONOMA DE MADRID

Other entities:

Sectors:

Health

Subsectors:

TRL Level:

TRL 4 – technology validated in lab

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

Applications

• Novel mode of action, different from other antivirals • Prophylactic antiviral effect • Suitable for acyclovir-resistant HSV-1 and HSV-2 • Synergistic activity in combination with acyclovir • Strong candidate for immunocompromised patiens •Safety and efficacy proven in preclinical in vivo models

Comments

Other related patents

Health

Photosensitizer, Pharmaceutical Composition Compounding It, and Its Use in Photodynamic Therapy

Countries

Spain

Health

Glycolipid mimetics with selective anti or pro-inflammatory response

Countries

Spain

Health

FACIAL PROTECTION ELEMENT FOR PROTECTION AGAINST RISKS OF EXPOSURE TO INFECTIOUS BIOLOGICAL AGENTS

Countries

Spain

Get back to patents directory